Synergism of dopamine plus furosemide in preventing acute renal failure in the dog  by Lindner, Armando et al.
Kidney International, Vol. 16 (1979), pp. 158 —166
Synergism of dopamine plus furosemide in preventing acute
renal failure in the dog
ARMANDO LINDNER, RALPH E. CUTLER, and WILLIAM G. GOODMAN
With the technical assistance of PETER A. PANSING and Rix KUE5TER
The Veterans Administration Medical Center and the University of Washington, Seattle, Washington
Synergism of dopamine plus furosemide in preventing acute re-
nal failure in the dog. The protective effects of a combination of
dopamine and furosemide were studied in dogs during the initial
phase of acute renal failure (ARF) induced by intravenous uranyl
nitrate (10 mg/kg). Fifteen minutes after injection of the nephro-
toxin, an infusion of dopamine (3 g/kg/min), furosemide (1 mgI
kglbolus followed by I rng/kg/hr), or both drugs simultaneous-
ly were given for 6 hours. Exogenous creatinine clearance was
measured for 6 hours, and the intrarenal blood flow was mea-
sured with radioactive microspheres before and 3 hours after the
induction of ARF. Treatment with both dopamine and furose-
mide produced renal vasodilatation, high urine flow rate, and at-
tenuation of the fall in GRF seen in untreated animals. In con-
trast, single use of dopamine or furosemide was totally inef-
fective in producing renal vasodilatation, a diuresis, or the
maintenance of the GFR. These data indicate that dopamine plus
furosemide have a synergistic effect in preventing the early
pathophysiologic changes associated with ARF in this animal
model. Maintenance of a high GFR correlated best with the en-
hancement of solute excretion and urine flow rate. Potential pro-
tective effects of dopamine plus furosemide in other models of
ARF deserve careful investigation.
Synergie de Ia dopamine et du furosémide dans Ia prevention de
l'insuffisance rénale aiguë du chien. Les effets protecteurs de
l'association de dopamine et de furosémide ont été étudiés chez
des chiens au cours de la phase initiale de l'insuffisance rénale
aiguë (ARF) déterminée par le nitrate d'uranyl intraveineux (10
mg/kg). Quinze minutes aprês l'injection néphrotoxique, une
perfusion de dopamine (3 g/kg/min), de furosemide (1 mg/kg de
dose de charge suivie de 1 mglkglhr), ou des deux drogues simul-
tanément, a été administrée pendant 6 heures. Le clearance de la
créatinine été mesuré pendant 6 heures, et le debit intra-rénal a
été mesuré, au moyen de microsphères radio-actives, avant et 3
heures après l'induction de l'insuffisance rénale aiguë. Le traite-
ment associant dopamine et furosémide produit une vasodilata-
tion rénale, un debit urinaire élevé, et atténue Ia chute de Ia
filtration glomerulaire qui est observée chez les animaux non
traités. Au contraire Ia dopamine seule ou le furosémide seul
sont totalement inefficaces en ce qui concerne Ia vasodilatation
rénale, Ia diurése ou le maintien du debit de filtration glomeru-
laire. Ces résultats indiquent que dopamine et furosémide ont un
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effet synergique dans la prevention des modifications physio-
pathologiques precoces associées a l'insuffisance rénale aiguë
dans ce modèle animal. Le maintien d'un debit de filtration glom-
érulaire élevé est très corrélé avec l'augmentation de l'excrétion
de substances dissoutes et le debit urinaire. Les effets pro-
tecteurs de 1' association dopamine-furosemide dans d'autres
modèles d'insuffisance rénale aigue méritent d'être étudiés.
The mechanisms responsible for the reduction in
renal function during the generation and mainte-
nance phases of acute renal failure remain unclear.
One factor, renal vasoconstriction, has been uni-
formly found in the initial phase of many animal
models [1—6]. In the model used in the present
study, uranyl nitrate-induced acute renal failure in
the dog, both Flamembaum et al [7] and Stein et al
[8] have shown a marked initial reduction in renal
blood flow. Similarly, vasoconstriction is common-
ly found during acute renal failure in man [9, 10].
Vasodilators have been effective in reducing the
renal vasoconstriction in animal studies [3, 6], as
well as in patients with acute renal failure [11, 12].
No improvement, however, in the GFR was shown
in these studies despite a reduction of renal vascular
resistance. It should be emphasized, however, that
renal failure was well established at the time of the
drug intervention and that vasodilators were often
used for short periods of time. In a recent study,
vasodilatation induced by prostaglandin E attenu-
ated the fall in insulin clearance after ARF induced
by intrarenal norepinephrine infusion but not after
uranyl nitrate [13]. Therefore, the role of vasocon-
striction and the protective effects of vasodilators
clearly deserve further evaluation.
It has been suggested that large doses of furose-
mide [14] or ethacrynic acid [15] may improve the
course of clinical acute renal failure. Recent re-
ports, however, cast doubt on the protective value
of diuretics in a clinical setting [16, 17]. Furosemide
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has been effective in some animal models [18—211.
At least in some cases, failure of protection seemed
due to late administration of the diuretic [16, 19,
20]. On the other hand, vasoconstriction has been
most frequently encountered during the generation
of acute renal failure [1—8]. Conceivably, the vaso-
constriction may have prevented access of furose-
mide to a critical intrarenal locus in cases of failure
of this treatment. In this context, a preliminary re-
port by Talley, Forland, and Beller [22] suggests
that a combination of a vasodilator (dopamine) with
furosemide may have reversed acute renal failure in
four patients. Therefore, the present study was un-
dertaken to investigate a possible synergistic effect
of subpressor doses of dopamine and furosemide in
preventing the generation phase of acute renal fail-
ure in the uranyl nitrate model of the dog.
Methods
Studies were performed in 28 mongrel dogs of ei-
ther sex, weighing 15 to 25 kg. Dogs were anesthe-
tized with pentobarbital (30 mg/kg) and ventilated
with a Harvard respirator. A permanent, soft poly-
vinyl catheter (I.D., 0.025 inches; O.D., 0.04 inch-
es) was implanted in the left atrium and exteriorized
through the skin. This simple method was devel-
oped in this hospital for injection of radioactive mi-
crospheres [23]. Dogs were allowed to recuperate
for 1 week, while on a regular diet, before they were
fasted for 24 hours prior to an experiment. At this
time, they were anesthetized and ventilated in a
similar manner; cannulas were inserted in the femo-
ral vein for infusions and in both femoral arteries for
blood collection and continuous blood pressure re-
cording. Both ureters were cannulated through a su-
prapubic incision.
A water load (20 mllkg) was given intravenously
over 30 mm in the form of 5% dextrose in water to
insure adequate urine flow. After baseline blood
samples had been obtained, a priming dose of
creatinine was given, and a maintenance infusion
was given to maintain a plasma concentration of
about 10 mg/dl. Urine collection periods averaged
30 mm and started after equilibration for 1 hour.
Ringer's lactate solution was infused continuously
at a rate to approximate urine losses.
All studies were done with each dog serving as its
own control. After equilibration, at least two 30-mm
renal clearance periods and a control RBF measure-
ment with radioactive microspheres were obtained.
Acute renal failure was then induced with an-
hydrous uranyl nitrate in a dose of 10 mg/kg, intra-
venously. RBF was measured again 3 hours after-
ward with microspheres of a different radionuclide.
This coincided with the early initiation phase of
acute renal failure analogous to the experimental
design in a previous study [24]. Thirty-minute renal
clearance periods were obtained for 6 hours after
uranyl nitrate injection. The kidneys were then re-
moved, and one was processed for gamma counting
as described below.
Four groups of studies were performed as fol-
lows: Group 1: Acute renal failure, untreated dogs
(N = 12): No therapeutic intervention was used af-
ter induction of acute renal failure with uranyl ni-
trate. Group 2: Acute renal failure, combined dopa-
mine and furosemide treatment (N = 8). Group 3:
Acute renal failure, dopamine treatment only (N =
4). Group 4: Acute renal failure, furosemide treat-
ment only (N = 4).
Microsphere measurements of RBF were done in
only four dogs in each group. Renal clearance stud-
ies were done in all animals. In groups 2 through 4,
treatment with dopamine, furosemide, or both
drugs combined was started intravenously 15 mm
after administration of uranyl nitrate and was con-
tinued for 6 hours. Furosemide was given as a 1 mg/
kg bolus, followed by 1 mg/kg/hr infusion. Dopa-
mine was infused at 3 g/kg/min. All drugs were dis-
solved in Ringer's lactate solution and given at 0.5
mllmin with a Harvard pump. Blood pressure was
generally unchanged. Occasionally, the dopamine
infusion rate required a 10 to 20% decrease to return
blood pressure to within 5 mm Hg of control values.
Radioactive microspheres were used to measure
the intracortical distribution of renal blood flow
(RBF) by the method of Stein et al [25]. Approxi-
mately 400,000 microspheres 15 in diameter (15 to
20 sCi) were given after sonication. Nuclides used
were 85Sr and '41Ce. A different nuclide was used in
each period, and the sequence of injections was al-
ternated in each experiment. The spheres were sus-
pended in 1-mi solution of 10% dextran and injected
through the left atrial catheter in about 10 sec and
then flushed with 20 ml of saline. In a situation such
as acute renal failure, however, there may be non-
homogeneous flow or patchy areas of cortical is-
chemia. Thus, sampling only two cortical areas may
not provide adequate information about the rest of
the cortex. Therefore, Stein's method [25] was ex-
tended as follows: at the end of the experiment, one
kidney was removed, weighed, and cut in five coro-
nal sections. From each of these, four cortical
squares 1 cm in width were obtained by dissection.
Then, specially designed kidney cutters (based on a
prototype provided by Dr. J. Stein, University of
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Texas, San Antonio) were used to obtain four cor-
tical sections of equal thickness, labeled I to IV
from the surface to the juxtamedullary area. This
method provided 80 cortical sections, sampled from
20 cortical areas. Each section was then placed in a
preweighed Packard Gamma counting tube, re-
weighed, and counted in a Packard autogamma
counter (Packard Instrument Co., Inc., Donners
Grove, Illinois). 85Sr was counted at the 0.510 meV
peak and 141Ce at the 0.145 meV peak. No correc-
tion was necessary for the 85Sr counts, but the '41Ce
counts were corrected by the channel crossover
method.
The formulas used were those previously de-
scribed [251. Thus, for each cortical zone I to IV,
we calculated the fractional distribution of blood
flow (the corrected percent zonal flow, PZ'), the
zonal blood flow (BFZ, mllmin), and the zonal per-
fusion rate (BFRZ, mllminlg). The corrected weight
of each cortical zone (WTZ) was obtained by using
the derivation of the volume of each zone (VZ), ac-
cording to McNay and Abe [26], who found the per-
cent of renal volume to be 27, 22, 17, and 12%,
in zones I to IV respectively. Finally, the relative
distribution of flow between the outer/inner cortex
(0/I) was calculated by the formula:
0/I = PZ'1 + PZ'1 / PZ'III + PZ',
In all studies, total RBF was measured with radio-
active microspheres, by using the reference sample
method described by Domenech et al [27]. This ob-
viated undue manipulation of the kidney in obtain-
ing renal blood flow. The validity of this method has
previously been demonstrated [28]. Furthermore,
this method was correlated with measurements of
PAll clearance during the control period in eight
dogs. The correlation coefficient measurements be-
tween these two methods was r = 0.99 (N = 8). The
reference sample was collected from the femoral ar-
tery catheter in a heparinized syringe withdrawn by
a precalibrated Harvard pump at 20 mllmin. The
pump was started 10 sec before injection and con-
tinued for 1 mm after administration of the spheres.
The sample was transferred to counting tubes after
rinsing the collection syringe with hemo-sol solu-
tion. The rinse was added to the counting tubes,
which were then centrifuged for 5 mm to sediment
the spheres. After the small tissue sections were
counted, they were recombined with the rest of the
kidney. Total cpm in the kidney were obtained by
dissolving it in 100 ml of concentrated sodium hy-
droxide for 24 to 48 hours. The tissue was then ho-
mogenized, and 5 g of dedocyl sodium sulfate and 5
ml of ethanol were added. After dispersion by soni-
fication, triplicate 1-ml aliquots of this suspension
were pipetted and counted in the same manner as
the tissue sections. Similarly, the reference blood
sample was counted at this time. This method was
found to give highly reproducible counts for the
whole kidney, with a coefficient of variation of 1%.
Total RBF was calculated by the following formula:
total cpm in blood
= cpm in kidney
blood withdrawal rate (mllmin) RBF (mllmin)
where cpm is counts per mm of the nuclide.
A computer program was adapted for a PDP-10
Digital® computer to calculate total RBF and its in-
tracortical distribution with the formulas described
above.
Plasma and urine creatinine and para-amino-
hippurate concentrations were determined by the
autoanalyzer method. Plasma and urine sodium and
potassium concentrations were measured by flame
photometry and osmolarity by freezing point de-
pression.
Student's paired t test was used for statistical
analysis of changes, with dogs as their own controls
and with the mean value from both kidneys. The
average of at least two control clearance periods
was used. Values used at 1, 3, and 6 hours represent
a composite of clearance measurements during the
30-mm period immediately preceding and following
each of these times. Two-way analysis of variance
with interaction [29] was used between group 1 (un-
treated dogs) and groups 2 to 4, respectively, to de-
termine the significance of changes induced by each
therapeutic intervention upon RBF and renal func-
tion measurements.
Results
A summary of the sequential changes in renal
function (group mean SEM) is shown in Table 1.
Group 1: Acute rena/failure, untreated dog (N =
/2). Administration of uranyl nitrate was followed
by a progressive fall in creatinine clearance in all
dogs. A significant (P < 0.02) fall occurred by the
first hour and continued to worsen through the sixth
hour (P < 0.001), when it was only 18% of control
values. Urine flow rate was generally unchanged at
1 and 6 hours. The only significant change (P <
0.02) was a modest elevation above control levels at
3 hours. Sodium excretion (UNaV) and the fraction
of filtered sodium excreted (EFFNa) rose within 1
hour, were maximally increased at 3 hours, and re-
mained significantly elevated at 6 hours. Urine os-
molarity (mOsm/liter) fell progressively from 825
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Table 1. Changes in renal function after uranyl nitrate injections
Time Urine flow
hr mi/mm
UNa1 EFFNa
p.Eqlmin %
Uo.,mV
pm/min
Ccr
mi/mm
Group 1: Untreated dogs (N = 12)
0
(control) 0.4 0.1 15 3 0.21 0.04 274 46 54.3 5.3
0.6 0.2 39 8 (P < 0.02) 0.97 0.27 (P < 0.02) 377 85 33.0 4.8 (P < 0.02)
3 1.3 0.3(P < .02) 137 34(P <0.003) 9.46 1.37(P <0.001) 478 111 13.6 4.1(P <0.001)
6 1.1 0.4 120 36(P < 0.01) 10.20 l.30(P < 0.001) 403 107 9.7 3.4(P < 0.001)
Group 2: Combined dopamine-furosemide (N = 8)
0
(control) 0.8 0.4 29 18 0.30 0.2 570 246 67.7 5.7
1 9.2 2.7(P <0.01) 975 331(P <0.02) 7.75 2.4(P <0.01) 2640 580(P <0.003) 96.0 11.1
3 8.5 1.5(P < 0.001) 909 160(P <: 0.001) 15.70 2.6(P < 0.001) 2164 343 (P < 0.002) 46.9 14.3
6 9.0 2.0 (P < 0.002) 1015 251 (P < 0.003) 24.60 4.3 (P < 0.001) 2347 503 (P < 0.003) 28.8 5.7 (P < 0.005)
Group 3: Dopamine only (N = 4)
0
(control) 0.2 0.4 11.3 7 0.12 0.08 203 35 64.2 6.8
1 0.6 0.2 106.0 53 1.10 0.58 1067 173 (P < 0.04) 65.2 4.9
3 1.5 0.6 251.0 106 7.50 3.97 760 237 25.5 4.4(P <0.025)
6 2.2 0.7 (P < 0.05) 334.0 96(P < 0.05) 12.10 4.59 953 198(P < 0.02) 20.4 1.9(P < 0.01)
Group 4: Furosemide only (N = 4)
0
(control) 0.2 0.5 16.8 6.5 0.22 0.09 249 55 55.0 11.1
1 5.3 1.0(P < 0.01) 594.0 117(P < 0.025) 22.60 7.30(P < 0.05) 1478 258(P < 0.02) 24.8 8.2
3 1.7 0.8 117.0 77 28.90 7.20(P < 0.025) 476 221 6.0 3.8(P < 0.005)
6 1.3 0.5 133.0 51 28.9 9.00(P < 0.05) 256 155 3.3 2.0(P < 0.001)
Values are the mean changes SEM.
during control to as low as 392 at 6 hours (P < 0.001).
On the other hand, osmolar excretion (UosmV) was
not significantly different in any study period.
Results of RBF studies are summarized in Table
2. RBF was measured in 4 of the 12 dogs studied in
group 1. Three hours after administration of uranyl
nitrate, mean RBF fell by 30%. The fractional distri-
bution of cortical flow (PZ', %) decreased signifi-
cantly in outer zone I, was unchanged in zone II,
and increased in inner zones III and IV. This result-
ed in a significant fall in the 0/I perfusion ratio from
4 to 2.4, further indicating a fractional redistribution
of flow to inner cortical nephrons. Zonal perfusion
rate was decreased significantly in outer zones I and
II and remained unchanged in inner zones III and
IV. Blood pressure was unchanged during the
study.
Groups 2 to 4: Acute rena/failure, treated dog (N
= 8 in group 2; N = 4 in groups 2 and 4). Treatment
with both dopamine and furosemide (group 2)
markedly attenuated the fall in creatinine clearance
after administration of uranyl nitrate. Creatinine
clearance initially rose to 142% of control within 1
hour. This probably represents a spurious elevation
due to the sudden rise in urine flow rate or "wash-
out" effect. Subsequently, it remained at 69 and
43% of the control value at 3 and 6 hours, respec-
tively. Only the fall at 6 hours was statistically sig-
nificant. In marked contrast, treatment with either
dopamine (group 3) or furosemide alone (group 4)
did not prevent an early, significant fall in GFR.
Major falls in glomerular filtration were observed in
both groups within 3 hours of receiving the nephro-
toxic agent.
Treatment with both dopamine and furosemide
(group 2) caused a brisk, persistent diuresis, and the
urine flow averaged 9 mllmin throughout the study
in contrast to the three other groups. In dogs given
dopamine only, a small increase in urine flow oc-
curred after 6 hours, reaching an average peak of
2.2 mllmin. In dogs receiving furosemide only, a
significant increase in urine flow was observed at 1
hour, but not thereafter.
Treatment with the combination of dopamine and
furosemide was followed by a large, persistent na-
triuresis. Sodium excretion (UNaV) and the excreted
fraction of filtered sodium (EFFNa) were markedly
increased after 1, 3, and 6 hours of infusion. In con-
trast, sodium excretion was modestly increased by
dopamine (group 3) only at 6 hours (P <0.05) and
by furosemide (group 4) only initially at 1 hour (P <
0.025). EFFNa was also higher than control at all
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Table 2. Summary of changes in renal blood flow in all groups of dogsa
Group
MBF
mi/mm
Fractional zonal (PZ' 1-TV), % Zonal rates (R I-IV), mi/minig 0/F'
%
- ---———
I H III IV I II III IV
Control 197 15
Group 1: Untreated
46.4 3 33.0 1.0 14.7 0.6 5.9 1.7 5.8 1.3 5.0 1.0 2.9 0.7 1.7 0.6 4.0 0.6
Exp.pd 140 10 37.1 4 32.9 1.3 20.3 1.0 9.8 2.2 3.3 0.6 3.6 0.8 2.9 0.7 2.0 0.6 2.4 0.3
P <0.002 <0.02 NS <0.005 <0.009 <0.028 <0.004 NS NS <0.01
Control 186 5 Group 2: Dopamine + furosemide47.4 4 34.2 4.6 13.1 1.6 2.9 0.6 4.5 0.3 4.0 0.6 2.0 0.3 0.6 0.1 5.5 1.1
Exp. pd 263 9 35.9 5 44.7 6.6 15.2 1.9 4.2 0.2 4.8 0.7 7.3 1.0 3.2 0.5 1.3 0.1 4.3 0.6
P <0.001 <0.026 <0.043 NS <0.034 NS <0.008 <0.048 <0.002 NS
Control 223 34
Group 3: Dopa,nmne only
44.3 2 33.1 1 17.1 1 5.6 0 8.1 1 7.4 1 4.9 1 2.8 0 3.5 0
Exp.pd 232 90 35.2 5 33.2 2 21.9 3 9.7 2 7.1 2 7.7 2 6.5 2 3.8 1 2.3 0
P NS NS NS NS NS NS NS NS NS NS
Control 237 22
Group 4: Furose,nide only
32.8 2.3 38.1 2.1 20.2 1.4 8.9 0.9 3.5 0.8 5.2 1.2 3.5 1.0 2.2 0.7 2.5 0.3
Exp. pd. 201 47 32.2 1.4 36.8 2.5 20.3 0.9 10.8 0.9 2.7 0.4 4.0 0.9 2.7 0.4 2.0 0.2 2.3 0.2
P NS NS NS NS NS NS NS NS NS
'Values are the group means SEM. Experimental period (exp. pd.) was 3 hours after uranyl nitrate administration. 0/I is blood flow
ratio between outer and inner cortical zones (see text).
times in furosemide-treated dogs, and it was not sig-
nificantly changed by single treatment with dopa-
mine. Osmolar excretion (UosmV) was markedly en-
hanced in all study periods by the combination of
dopamine and furosemide. Lesser, inconsistent in-
creases in UösmV were found at 1 and 3 hours in
group-3 dogs, and only at 1 hour in group 4.
With untreated dogs as comparison (group 1),
two-way analysis of variance indicated a specific ef-
fect of combined dopamine and furosemide treat-
ment in maintaining creatinine clearance and in-
creasing urine flow rate, sodium, and osmolar ex-
cretion (P < 0.01, respectively) at 1, 3, and 6 hours
after uranyl nitrate injection. In contrast, protection
of glomerular filtration in dogs receiving dopamine
only (group 3) was short-lasting and differed from
untreated dogs only at 1 hour (P < 0.01), whereas
urine flow, sodium, and osmolar excretion were not
significantly different. Finally, in dogs receiving fu-
rosemide (group 4), changes in creatinine clearance
were never different from those in untreated dogs.
In this group, transient differences in urine flow, so-
dium, and osmolar excretion (P <0.01 in each case)
were only observed during the first hour after ura-
nyl nitrate.
Combined administration of dopamine plus fu-
rosemide was associated with an increase in mean
renal blood flow of 41% (Table 2), in marked con-
trast to the severe vasoconstriction observed in un-
treated dogs 3 hours after injection of uranyl nitrate.
The fractional distribution of cortical flow de-
creased only in outer zone I (P < 0.026), and it was
significantly increased in zones II and IV. The in-
crease in zone III was just below significance level.
The Oil cortical flow ratio was not statistically dif-
ferent from controls obscuring the marked increase
in fractional flow to outer cortical zone II. Zonal
flow rate was unchanged in zone I and significantly
increased in zones II, III, and IV. These changes
were in opposite direction to those in untreated
dogs.
Administration of dopamine only (group 3) or fu-
rosemide (group 4) was associated with no signifi-
cant changes in either mean RBF, fractional distri-
bution of cortical flow, zonal flow rate, or the 0/I
cortical perfusion ratio (Table 2). The only ex-
ception was a rise in fractional flow to zone TV in
furosemide-treated dogs (P < 0.004). In dogs
treated with dopamine only, there was a tendency
toward a redistribution of flow to the inner cortical
zones in three of four dogs. Mean values, however,
were not statistically significant.
The marked enhancement in mean RBF (P < 0.1)
and the attenuation of the shift toward inner neph-
rons, that is, smaller fall in 0/I ratio (P < 0.05) and a
rise in fractional flow to zone II (P < 0.01), that
occurred in group-2 dogs were significantly dif-
ferent from changes in untreated dogs, as shown by
analysis of variance.
A significant correlation was found between
mean blood flow at 3 hours and the subsequent pro-
tection against a fall in creatinine clearance at 6
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hours (r = 0.52, P < 0.038, d.f. = 14). Furthermore,
when all groups were analyzed together (d.f. = 26),
strong statistical correlations were found between
protection of renal function at 6 hours and the fol-
lowing: urine flow rate (r = 0.686, P < 0.01), so-
dium excretion (r = 0.745, P < 0.01), and osmolar
excretion (r = 0.776, P < 0.01) during the preceding
3 hours. Moreover, protection of renal function at 6
hours correlated well with the simultaneously mea-
sured urine flow rate (r = 0.769, P < 0.01), sodium
excretion (r = 0.786, P < 0.01), and osmolar excre-
tion (r = 0.817, P < 0.01). In group 2 (dopamine-
furosemide combination), strong correlations were
found with the same variables, in particular with os-
molar excretion at 6 hours (r = 0.909, P < 0.01, d.f.
= 6). In contrast, no such correlations were found
in dogs receiving either dopamine or furosemide
alone, although the number of samples was very
small in these two groups (N = 4, d.f. = 2).
Discussion
The present study evaluates a possible syner-
gistic effect of vasodilators and diuretics in pre-
venting the fall in GFR during the initial phase of
acute renal failure. Uranyl nitrate nephrotoxicity, a
well-known experimental model, was used in the
dog. Treatment with either dopamine, furosemide,
or a combination of both drugs was started shortly
after injection of the nephrotoxic agent.
The results indicate that the combination of dopa-
mine with furosemide is indeed synergistic. This
treatment greatly attenuates the reduction in renal
function and concomitantly induces a brisk diuresis
and natriuresis which persists during the first 6
hours of drug infusion after injection of uranyl ni-
trate. In contrast, treatment with dopamine or fu-
rosemide given separately affords no protection of
renal function.
The pathophysiology of acute renal failure has
been reviewed recently [30]. It is now apparent that
the initiation and maintenance phases of this condi-
tion may be associated with different pathogenic
mechanisms. Furthermore, the causal mechanisms
may differ in hemodynamically mediated and neph-
rotoxic models of acute renal failure [30]. One fac-
tor, vasoconstriction, has been uniformly found in
the initiation phase of several ischemic animal mod-
els [1-3, 6]. The findings in the uranyl nitrate model
have been less consistent. Blantz [31] found no
changes in RBF using this agent in the rat. The re-
sults, however, of the present study in the dog con-
firm earlier findings by Flamembaum et a! [7, 24]
and Stein et a! [8] in demonstrating a marked renal
vasoconstriction 3 hours after administration of a
large dose of uranyl nitrate. In addition, there was a
redistribution of blood flow to inner cortical areas.
The separate administration of dopamine or furose-
mide prevented the vasoconstriction and the redis-
tribution toward the inner cortex, but both drugs to-
gether induced a marked renal vasodilatation (41%
above control values) and a rise in flow rate to all
zones but the most superficial (zone I).
These results are particularly meaningful because
dogs were used as their own controls, and a reliable
method for measuring intrarenal blood flow was
used. Furthermore, the radioactive microspheres
method [25] was extended to measure flow from 20
instead of 2 cortical areas. The failure to demon-
strate vasoconstriction in other studies with the ura-
nyl nitrate model may have been due to the low
dose used [32], the measurements of blood flow too
late during the maintenance phase [33, 34], or the
methods (diodrast extraction) used to measure
blood flow [34].
The single use of dopamine or furosemide con-
firms earlier observations in animal models [3, 6], as
well as patients with acute renal failure [11, 12]. In
all instances, reversal of the vasoconstriction was
achieved without concomitant protection of renal
function. This is analogous to findings by Mauk et al
[13] with prostaglandin E (PGE) in the uranyl ni-
trate model. The fall in GFR despite normal renal
blood flow in dogs receiving dopamine, furosemide,
or PGE alone [13] implies that factors in addition to
vasoconstriction must have contributed to the renal
functional impairment such as a decrease in the gb-
merular capillary wall ultrafiltration coefficient [6,
31], or back leakage of filtrate across damaged tubu-
lar epithelium [8].
In the current study, early and continuous admin-
istration of dopamine plus furosemide induced a
marked renal vasodilatation which was significantly
correlated with the subsequent protection of GFR.
Therefore, a protective role for a major renal vaso-
dilatation during the generation of renal failure
cannot be excluded.
Furosemide and ethacrynic acid have been re-
ported to improve the course of acute renal failure
in patients [14, 15] and in several animal studies
[18—20]. This effect has not been confirmed in a re-
cent randomized study in 66 patients [17]. It ap-
pears that beneficial effects of furosemide cannot be
demonstrated late during the maintenance phase of
acute renal failure, either in patients [16] or in ani-
mal models [211].
The possible mechanism(s) of protection by fu-
rosemide have not been elucidated. One effect of
furosemide, renal vasodilatation, may be mediated,
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at least in part, by prostaglandins because it can be
inhibited by indomethacin [35]. Furthermore, uri-
nary excretion of PGE increases concomitantly
with the renal hernodynamic effects of furosemide
[36]. It would he of interest to quantitate prostaglan-
din excretion after concomitant administration of
furosemide and dopamine since a significant vaso-
dilatation was found in the present study only when
both drugs were given simultaneously.
Several mechanisms may be proposed to explain
the combined action of dopamine and furosemide:
First, the activation of a glomerulotubular feedback
mechanism has been suggested by Thurau and Boy-
lan [37] and Mason [38] to explain the pathogenesis
of acute renal failure. A similar mechanism was pro-
posed by Flamembaum, Hamburger, and Kaufman
[391 for the uranyl nitrate model in the rat. Furose-
mide but not acetazolamide is able to block the de-
crease in GFR induced by rapid perfusion of
Henle's loop [40]. A very high concentration of fu-
rosemide at the macula densa, in excess of 0.5 x
l0 M, is required, however, for a 90% blockade of
glomerulotubular feedback [41]. Thus, vasocon-
striction may prevent adequate access of furose-
mide to the macula densa. Moreover, although fu-
rosemide itself may increase RBF [42], single use of
the diuretic in this study did not produce a signifi-
cant vasodilatation. Therefore, it seems conceiv-
able that combination of furosemide with a vaso-
dilator may have increased delivery of the diuretic
to the macula densa.
Second, increased delivery of furosemide may
have modulated the rate of renin production in re-
sponse to the distal solute load [40, 41]. However,
recent preliminary studies demonstrated that sup-
pression of intrarenal renin has no protective effect
in the renal ischemia model [41, 43]. Similarly, renin
blockade with angiotensin antagonists and convert-
ing enzyme inhibitors did not improve the GFR de-
spite the induction of vasodilatation 3 hours after
glycerol administration in the rat [44]. Therefore,
the role of renin in the generation of acute renal fail-
ure remains uncertain. The participation of other
mediators of tubuloglomerular feedback [45] must
also be determined. Prostaglandins, in particular,
deserve attention because they seem related to the
effects of furosemide [35, 36] and produce a vasodil-
atation, as discussed above.
Third, protection of GFR with a combination of
dopamine and furosemide may be related to the in-
duction of a brisk diuresis and a massive increase in
solute excretion. This is supported by the strong
correlations found between the rates of urine flow,
sodium, and particularly osmolar excretion and the
subsequent maintenance of the GFR. In this regard,
Thiel et al [19] have suggested that a brisk diuresis
without renin suppression affords protection against
mercuric chloride in the rat kidney. Similarly, the
protective effects of mannitol in norepinephrine-in-
duced acute renal failure correlated with solute ex-
cretion rate [46]. Conceivably, this could attenuate
any relative tubular obstruction. The latter patho-
genic mechanism, however, has not been found in
the uranyl nitrate model [8, 31]. On the other hand,
the increased solute excretion may have contrib-
uted to reduce tubular cell swelling, as shown with
mannitol [47], and with polyethylene-glycol [48]
during ischemic renal damage in the rat.
Fourth, alterations in the glomerular ultrafiltra-
tion coefficient (Kf) have been proposed to explain
the cessation of filtration despite an increase in total
RBF in two animal models [6, 8, 31]. In both mod-
els, late alterations in glomerular epithelial cell
structure were described 48 hours after the renal in-
sult. A causal role of these changes in the initiation
of acute renal failure is uncertain. In this context,
angiotensin II causes a marked vasoconstriction
and presumably a decrease in surface area of the
glomerular capillaries [49]. Therefore, a possible ef-
fect of the combination of dopamine and furosemide
in these studies may have been an increase in capil-
lary surface area and thus in Kf as a consequence of
the vasodilatation.
Finally, biochemical alterations have been pro-
posed as the initial event in nephrotoxic acute renal
failure [30]. The inhibitory effects of both uranyl ni-
trate and mercuric chloride on sodium reabsorption
in vitro can be reversed by dithiothreitol (DTT), a
heavy metal chelator [50]. In addition, DTT
markedly ameliorated heavy metal-induced renal
failure in the rat [51]. In contrast to DTT, which
prevented a rise in fractional sodium excretion fol-
lowing injection of uranyl nitrate [51], treatment
with a combination of dopamine and furosemide re-
sulted in a marked natriuresis. Thus, it seems very
unlikely that these drugs may prevent the biochemi-
cal alterations in proximal tubular cell transport ob-
served in this model.
Conclusion. This study demonstrates a synergistic
effect of a combination of dopamine and furosemide
in preventing the initiation of acute renal failure in
the uranyl nitrate model in the dog. It seems likely
that the mechanism(s) of protection may be multi-
factorial and may include a major role for an in-
crease in solute excretion and urine flow rate and a
blockade of a tubuloglomerular feedback mecha-
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nism. The vasodilatation may have contributed by
increasing delivery of furosemide to the macula
densa, or by affecting the glomerular ultrafiltration
coefficient (Kf), or both. An effect upon the renin-an-
giotensin or the prostaglandin systems may have
occurred as well.
Although this model may not be completely anal-
ogous to the clinical setting, the results suggest pos-
sible avenues of investigation for the treatment of
acute renal failure in patients. Early treatment with
vasodilators and diuretics is more likely to be ef-
fective when a renal insult is short lasting, that is,
intraoperative hypotension or hypovolemia, rather
than persistent, as is the case with the heavy metal
models. In this context, the positive preliminary re-
sults of Talley, Forland, and Belier [22] using dopa-
mine plus furosemide in cases of acute renal failure,
as well as our own personal experience with pa-
tients, appear very encouraging.
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